Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2021 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update

Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer Appointed Meeta Chatterjee, Ph.D., to Board...
February 18, 2021 16:02 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...
February 08, 2021 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy)...
January 20, 2021 22:30 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Pricing of Offering of Common Stock

CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares...
January 19, 2021 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Offering of Common Stock

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its...
January 11, 2021 06:05 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates Provides EDIT-301 updates, including timeline for dosing sickle cell disease patients in the Phase 1/2 RUBY...
January 11, 2021 06:02 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared...
January 11, 2021 06:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Transition of Chief Scientific Officer

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright,...
January 04, 2021 16:05 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th...
December 17, 2020 16:05 ET | Source: Editas Medicine, Inc.

Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its...